The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how data infrastructure stocks fared in Q4, starting with Oracle (NYSE:ORCL).

Generating insights from system level data is an increasing priority for most businesses, but to do so requires connecting and analyzing piles of data stored and siloed in separate databases. This is the demand driver for cloud based data infrastructure software providers, who can more readily integrate, distribute and process information vs. legacy on-premise software providers.

The 5 data infrastructure stocks we track reported a mixed Q4. As a group, revenues missed analysts’ consensus estimates by 4% while next quarter’s revenue guidance was 0.5% below.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 13.1% since the latest earnings results.

Oracle (NYSE:ORCL)

Starting as a database company in 1977 and now powering mission-critical systems across the globe, Oracle (NYSE:ORCL) provides enterprise software and hardware products and services that help businesses manage their information technology needs.

Oracle reported revenues of $16.06 billion, up 14.2% year on year. This print fell short of analysts’ expectations by 0.8%. Overall, it was a softer quarter for the company with a slight miss of analysts’ revenue estimates and a miss of analysts’ billings estimates.

“Oracle is very good at building and running high-performance and cost-efficient cloud datacenters,” said Oracle CEO, Clay Magouyrk.

Unsurprisingly, the stock is down 35.1% since reporting and currently trades at $144.75.

Best Q4: Teradata (NYSE:TDC)

Pioneering data warehousing technology in the 1980s before “big data” was a common term, Teradata (NYSE:TDC) provides cloud-based data analytics and AI platforms that help large enterprises integrate, analyze, and leverage their data across multiple environments.

Teradata reported revenues of $421 million, up 2.9% year on year, outperforming analysts’ expectations by 5.4%. The business had an exceptional quarter with EPS guidance for next quarter exceeding analysts’ expectations and an impressive beat of analysts’ EBITDA estimates.

Teradata achieved the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 7.1% since reporting. It currently trades at $31.32.

Is now the time to buy Teradata? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: C3.ai (NYSE:AI)

Named after the three Cs of its original focus—carbon, cloud computing, and customer relationship management—C3.ai (NYSE:AI) provides enterprise AI software that helps organizations develop, deploy, and operate large-scale artificial intelligence applications across various industries.

C3.ai reported revenues of $53.26 million, down 46.1% year on year, falling short of analysts’ expectations by 29.6%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and revenue guidance for next quarter missing analysts’ expectations significantly.

C3.ai delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update in the group. As expected, the stock is down 23% since the results and currently trades at $7.97.

Elastic (NYSE:ESTC)

Built on the powerful open-source Elasticsearch technology that powers search functionality for thousands of websites worldwide, Elastic (NYSE:ESTC) provides a search and AI platform that helps organizations find insights from their data, monitor applications, and protect against security threats.

Elastic reported revenues of $449.9 million, up 17.7% year on year. This print topped analysts’ expectations by 2.6%. Overall, it was a strong quarter as it also recorded an impressive beat of analysts’ EBITDA estimates and full-year EPS guidance exceeding analysts’ expectations.

Elastic achieved the highest full-year guidance raise among its peers. The stock is down 15% since reporting and currently trades at $52.35.

Confluent (NASDAQ:CFLT)

Built by the original creators of Apache Kafka, the popular open-source messaging system, Confluent (NASDAQ:CFLT) provides a data infrastructure platform that enables organizations to connect their applications, systems, and data layers around real-time data streams.

Confluent reported revenues of $314.8 million, up 20.5% year on year. This number beat analysts’ expectations by 2.2%. It was a strong quarter as it also produced an impressive beat of analysts’ EBITDA estimates and a decent beat of analysts’ revenue estimates.

Confluent delivered the fastest revenue growth among its peers. The company added 34 enterprise customers paying more than $100,000 annually to reach a total of 1,521. The stock is flat since reporting and currently trades at $30.59.

Vertically integrated manufacturing solutions provider Mayville Engineering Company (NYSE:MEC) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 10.7% year on year to $134.3 million. On the other hand, next quarter’s revenue guidance of $140 million was less impressive, coming in 2.5% below analysts’ estimates. Its non-GAAP loss of $0.08 per share was in line with analysts’ consensus estimates.

Mayville Engineering (MEC) Q4 CY2025 Highlights:

• Revenue: $134.3 million vs analyst estimates of $134.1 million (10.7% year-on-year growth, in line)
• Adjusted EPS: -$0.08 vs analyst estimates of -$0.07 (in line)
• Adjusted EBITDA: $6.31 million vs analyst estimates of $11.1 million (4.7% margin, 43.1% miss)
• Revenue Guidance for Q1 CY2026 is $140 million at the midpoint, below analyst estimates of $143.6 million
• EBITDA guidance for the upcoming financial year 2026 is $55 million at the midpoint, below analyst estimates of $66.57 million
• Operating Margin: -4.1%, down from 19% in the same quarter last year
• Free Cash Flow Margin: 7.6%, down from 29.4% in the same quarter last year
• Market Capitalization: $437.7 million

“We closed fiscal 2025 with strong momentum within our Data Center & Critical Power end market, securing $15 million of incremental project awards during the fourth quarter, strengthening our 2026 orderbook,” said Jag Reddy, President and Chief Executive Officer.

Company Overview

Originally founded solely on tool and die manufacturing, Mayville Engineering Company (NYSE:MEC) specializes in metal fabrication, tube bending, and welding to be used in various industries.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Mayville Engineering’s sales grew at a decent 8.9% compounded annual growth rate over the last five years. Its growth was slightly above the average industrials company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Mayville Engineering’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 3.6% over the last two years.

Mayville Engineering also breaks out the revenue for its most important segments, Commercial Vehicle and Construction & Access, which are 28.6% and 14.3% of revenue. Over the last two years, Mayville Engineering’s Commercial Vehicle revenue (exhaust, engine components, fuel systems) averaged 17.5% year-on-year declines while its Construction & Access revenue (fenders, hoods, frames for heavy machinery) averaged 13.7% declines.

This quarter, Mayville Engineering’s year-on-year revenue growth was 10.7%, and its $134.3 million of revenue was in line with Wall Street’s estimates. Company management is currently guiding for a 3.3% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 10.4% over the next 12 months, an improvement versus the last two years. This projection is admirable and indicates its newer products and services will spur better top-line performance.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Operating Margin

Mayville Engineering’s operating margin has generally stayed the same over the last 12 months, averaging 2.9% over the last five years. This profitability was lousy for an industrials business and caused by its suboptimal cost structureand low gross margin.

Looking at the trend in its profitability, Mayville Engineering’s operating margin might fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

In Q4, Mayville Engineering generated an operating margin profit margin of negative 4.1%, down 23.1 percentage points year on year. Since Mayville Engineering’s operating margin decreased more than its gross margin, we can assume it was less efficient because expenses such as marketing, R&D, and administrative overhead increased.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Mayville Engineering’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.

In Q4, Mayville Engineering generated an operating margin profit margin of negative 4.1%, down 23.1 percentage points year on year. Since Mayville Engineering’s operating margin decreased more than its gross margin, we can assume it was less efficient because expenses such as marketing, R&D, and administrative overhead increased.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Mayville Engineering’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.

Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business.

Sadly for Mayville Engineering, its EPS declined by more than its revenue over the last two years, dropping 55.2%. This tells us the company struggled to adjust to shrinking demand.

We can take a deeper look into Mayville Engineering’s earnings to better understand the drivers of its performance. Mayville Engineering’s operating margin has declined over the last two years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q4, Mayville Engineering reported adjusted EPS of negative $0.08, down from negative $0.07 in the same quarter last year. This print missed analysts’ estimates, but we care more about long-term adjusted EPS growth than short-term movements. Over the next 12 months, Wall Street expects Mayville Engineering’s full-year EPS of $0.16 to grow 163%.

Key Takeaways from Mayville Engineering’s Q4 Results

We struggled to find many positives in these results. Its full-year EBITDA guidance missed and its EBITDA fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 2.9% to $20.49 immediately after reporting.

Mayville Engineering underperformed this quarter, but does that create an opportunity to invest right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

If you have been wondering whether XPeng’s share price still lines up with its underlying worth, this is a good moment to take a closer look at what the current market price might be implying.

XPeng last closed at US$16.99, with returns of a 3.2% decline over 7 days, a 5.5% decline over 30 days, a 16.8% decline year to date, a 16.1% decline over 1 year, an 81.3% gain over 3 years, and a 36.9% decline over 5 years. Taken together, these moves raise questions about how investors are reassessing both risk and potential.

Recent coverage around XPeng has continued to focus on its role in the electric vehicle space, alongside attention on how sentiment toward growth oriented auto names is evolving. This mix of optimism and caution helps explain why the share price has seen both sharp gains over a multi year period and pullbacks over shorter time frames.

On our framework, XPeng earns a valuation score of 3 out of 6, which means it screens as undervalued on half of the checks we run. Next we will walk through the usual valuation tools investors rely on before finishing with a more complete way to think about what the stock might be worth.

Find out why XPeng’s -16.1% return over the last year is lagging behind its peers.

Approach 1: XPeng Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow (DCF) model takes estimates of the cash XPeng could generate in the future and discounts those back to today to arrive at an implied value per share.

On this 2 Stage Free Cash Flow to Equity model, XPeng currently has last twelve months free cash flow of about CN¥5.1b in outflows, so the starting point is a cash burn rather than surplus cash generation. Analysts provide explicit forecasts out to 2027, with free cash flow for that year estimated at CN¥10.8b. Beyond that, Simply Wall St extrapolates further cash flows through to 2035, with projected figures for each year ranging from CN¥8.2b to CN¥22.0b, all in CN¥.

When those projected cash flows are discounted back and combined with an estimate for value beyond the explicit forecast period, the model arrives at an intrinsic value of about US$26.55 per share. Against the recent share price of US$16.99, this implies XPeng trades at roughly a 36.0% discount to this DCF estimate, which suggests the shares are screening as undervalued on this method alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests XPeng is undervalued by 36.0%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: XPeng Price vs Sales

For companies that are still building toward consistent profitability, the price to sales, or P/S, ratio is often more useful than earnings based measures, because it focuses on what investors are paying for each dollar of revenue rather than profits that may still be volatile.

Growth expectations and risk still matter here, because a higher growth and higher risk business will usually trade on a higher “normal” P/S ratio than a slower growing, lower risk one. XPeng currently trades on a P/S of 1.58x, compared with the Auto industry average of 0.60x and a peer group average of 2.12x.

Simply Wall St’s Fair Ratio for XPeng is 1.46x. This proprietary measure estimates what a reasonable P/S multiple could be, after adjusting for factors such as earnings growth, profit margins, industry, market cap and company specific risks. That makes it a fuller reference point than a simple comparison with peers or the broad industry, which may not share XPeng’s exact growth profile or risk characteristics.

Against that Fair Ratio of 1.46x, XPeng’s actual 1.58x P/S is slightly higher, which suggests the shares are screening as overvalued on this measure.

Result: OVERVALUED

Upgrade Your Decision Making: Choose your XPeng Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, which are short, user friendly stories that tie your view on XPeng’s business to a set of revenue, earnings and margin assumptions. These are converted into a fair value and compared with the current price to help you decide how you feel about the stock, and then that view is kept automatically refreshed as new news or earnings arrive. For example, one XPeng Narrative on the Community page might lean cautious with a fair value anchored near the lowest analyst target of US$18.24. Another might be more optimistic with a fair value closer to the highest target of US$35.78. Both of these views sit side by side so you can see how different assumptions about XPeng’s future lead to very different implied values.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how financial exchanges & data stocks fared in Q4, starting with FactSet (NYSE:FDS).

Financial exchanges and data providers operate trading platforms and sell market information. They enjoy relatively stable revenue from trading fees and subscriptions, increasing demand for data analytics, and expansion opportunities in emerging markets. Challenges include regulatory oversight of market structure, competition from alternative trading venues, and substantial technology investments needed to maintain low-latency trading infrastructure and data security.

The 10 financial exchanges & data stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 0.8%.

In light of this news, share prices of the companies have held steady as they are up 3.7% on average since the latest earnings results.

FactSet (NYSE:FDS)

Founded in 1978 when financial data was still primarily delivered through paper reports, FactSet (NYSE:FDS) provides financial data, analytics, and technology solutions that investment professionals use to research, analyze, and manage their portfolios.

FactSet reported revenues of $607.6 million, up 6.9% year on year. This print exceeded analysts’ expectations by 1.3%. Despite the top-line beat, it was still a mixed quarter for the company with a solid beat of analysts’ EBITDA estimates but full-year EPS guidance slightly missing analysts’ expectations.

Unsurprisingly, the stock is down 27.4% since reporting and currently trades at $215.00.

Best Q4: Morningstar (NASDAQ:MORN)

Founded in 1984 by Joe Mansueto with just $80,000 in personal savings, Morningstar (NASDAQ:MORN) provides independent investment data, research, and analysis tools that help investors, advisors, and institutions make informed financial decisions.

Morningstar reported revenues of $641.1 million, up 8.5% year on year, outperforming analysts’ expectations by 2.2%. The business had an exceptional quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ EBITDA estimates.

Morningstar scored the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 18.9% since reporting. It currently trades at $183.16.

Weakest Q4: S&P Global (NYSE:SPGI)

Tracing its roots back to 1860 when it published the first railroad industry manual, S&P Global (NYSE:SPGI) provides credit ratings, market intelligence, commodity data, automotive analytics, and financial indices that help investors and businesses make decisions.

S&P Global reported revenues of $3.92 billion, up 9% year on year, in line with analysts’ expectations. It was a slower quarter as it posted full-year EPS guidance meeting analysts’ expectations and a miss of analysts’ EPS estimates.

As expected, the stock is down 1% since the results and currently trades at $439.71.

Moody’s (NYSE:MCO)

Founded in 1900 during America’s railroad boom when investors needed reliable information on bond risks, Moody’s (NYSE:MCO) provides credit ratings, risk assessment tools, and analytical solutions that help organizations evaluate financial risks and make informed investment decisions.

Moody’s reported revenues of $1.89 billion, up 13% year on year. This print surpassed analysts’ expectations by 1.6%. Overall, it was a strong quarter as it also recorded full-year EPS guidance meeting analysts’ expectations and a beat of analysts’ EPS estimates.

The stock is up 12.7% since reporting and currently trades at $477.00.

MarketAxess (NASDAQ:MKTX)

Pioneering the shift from phone-based to electronic bond trading since 2000, MarketAxess (NASDAQ:MKTX) operates electronic trading platforms that enable institutional investors and broker-dealers to efficiently trade fixed-income securities like corporate and government bonds.

MarketAxess reported revenues of $209.4 million, up 3.5% year on year. This result lagged analysts’ expectations by 0.9%. Taking a step back, it was a mixed quarter as it also recorded a beat of analysts’ EPS estimates but a slight miss of analysts’ EBITDA estimates.

MarketAxess had the weakest performance against analyst estimates and slowest revenue growth among its peers. The stock is up 18% since reporting and currently trades at $192.15.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after investors reviewed its recent performance metrics, including a past 3 months total return of 25.97% and annual revenue of US$17.26b with net income of US$1.41b.

At a share price of US$33.86, Teva’s short term share price returns over 7 and 30 days have been relatively muted. However, the 90 day share price return of 25.97% and very strong 1 year total shareholder return of 111.62% point to momentum that has built meaningfully over the past year.

If Teva’s rebound has you rethinking where growth could come from next, it may be worth scanning 27 healthcare AI stocks as another way to spot health related opportunities tied to data and automation.

With Teva reporting US$17.26b in revenue, US$1.41b in net income and trading at US$33.86, plus an indicated 42.63% intrinsic discount, is the market offering a genuine entry point or already pricing in future growth?

Most Popular Narrative: 10.8% Undervalued

Teva Pharmaceutical Industries’ most followed valuation story currently anchors fair value at US$37.95 per share versus the last close at US$33.86, framing the stock as trading below that narrative fair value while hinging heavily on future execution in R&D and affordable medicines.

Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme. Here is how bullish and cautious views are shaping up around valuation, execution, and growth.

Read the complete narrative.

Curious what sits behind that fair value gap and the 2026 focus point? The narrative leans on a specific revenue glide path, firmer profit margins, and a future earnings multiple that assumes investors reward consistent execution rather than just short bursts of progress.

Result: Fair Value of $37.95 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could change quickly if reliance on a few branded drugs, pressure on affordable medicines pricing, or a heavy US$15b plus debt load start to bite.

Find out about the key risks to this Teva Pharmaceutical Industries narrative.

Another Angle On Valuation

The fair value narrative presents Teva as 10.8% undervalued at US$33.86, but the price tag tells a different story. On a 28x P/E, the shares trade above the US Pharmaceuticals industry at 20x, peers at 21.2x, and the 24.3x fair ratio indicated by our model.

This gap suggests investors are already paying a premium for execution and growth that involve risk. If the market moves closer to the fair ratio, how comfortable are you with the valuation cushion at today’s price?

Alibaba Group Holding (BABA) has put artificial intelligence at the center of its story, rolling out a low cost AI coding platform, a bundled multi model subscription, and self developed chips.

Even with the AI push in coding tools and self developed chips, Alibaba Group Holding’s share price has faced pressure recently, with a 30 day share price return of 15.01% and a year to date share price return of 7.47%, while the 1 year total shareholder return of 10.57% and 3 year total shareholder return of 69.05% point to stronger momentum over longer periods than over the past few months.

If Alibaba’s AI push has caught your attention, it could be a good moment to broaden your watchlist with other names in the space through our 30 AI small caps.

With Alibaba trading at $144.11, sitting at an estimated 48% intrinsic discount and about 39% below one analyst price target, you have to ask: is this genuine value, or is the market already discounting future growth?

Most Popular Narrative: 43.3% Undervalued

At $144.11, the most followed narrative on Alibaba Group Holding pegs fair value far higher, which puts a bright spotlight on how that figure is built.

Alibaba Group’s future is increasingly promising, supported by strong fundamentals and a compelling valuation relative to risk free benchmarks. Using a forward earnings based approach, the company’s fair value is estimated at $318 per share. When adjusted for the current 10 year U.S. Treasury yield, this implies a risk adjusted intrinsic value of $254, already reflecting a prudent 20% discount to account for macroeconomic and interest rate dynamics. However, acknowledging investor concerns specific to Chinese equities including regulatory and geopolitical considerations, we apply an additional, conservative liquidity and country risk discount of 40% to the base fair value. This yields a target entry price of $203, representing a margin of safety for long term investors. At this level, Alibaba is described as offering downside protection as well as the possibility of upside if sentiment normalizes, earnings recover, and valuation gaps narrow. In today’s market, this narrative presents Alibaba as a global tech leader that combines scale, profitability, and discounted valuation.

Read the complete narrative.

Want to see what is behind that $254 fair value and $203 entry level, according to jaikhom? The narrative leans heavily on forward earnings, margin assumptions and a premium profit multiple usually reserved for large tech platforms. Curious which specific growth and profitability forecasts are used to justify such a wide gap to today’s price? The full story joins those moving parts into one value thesis.

Result: Fair Value of $254 (UNDERVALUED)

However, this story could look very different if regulatory pressures on Chinese tech tighten further, or if sentiment toward China focused equities weakens again.

Recent performance snapshot

ZTO Express (Cayman) (ZTO) has drawn fresh attention after a recent move that leaves the stock up about 11% over the past month and 17% in the past 3 months.

With the share price at $24.38, ZTO Express (Cayman) has a 30 day share price return of 11.17% and a 90 day share price return of 17.21%, while the 1 year total shareholder return of 30.11% contrasts with a more muted 8.16% total shareholder return over three years and a negative 22.16% total shareholder return over five years. This suggests momentum has picked up recently after a tougher longer term track record.

If this move in a logistics name has your attention, it could be a good moment to see what else is setting up, starting with our screener of 19 top founder-led companies.

With ZTO trading at $24.38 and sitting only around 2% below the average analyst price target, but implying a much larger intrinsic discount, you have to ask: is this a genuine mispricing, or is the market already baking in future growth?

Most Popular Narrative: 2.1% Overvalued

With the most followed narrative putting fair value at $23.87 compared to the recent $24.38 close, the gap is small, but the earnings story doing the heavy lifting behind that number is worth understanding.

Cost-saving initiatives around automation, digitization, and AI (such as remote-managed 3D digital models, autonomous vehicles, and AI customer service) are being rapidly deployed and already yielding measurable reductions in unit costs (e.g., a 1/3 reduction in frontline management headcount, over 60% drop in missorting). Continued scaling of these innovations is likely to further boost margin expansion and earnings sustainability.

Want to see what kind of revenue climb, margin profile, and future earnings multiple are baked into that fair value tag? The narrative leans on steady volume gains, firmer pricing, and a richer mix of higher value parcels to justify its outlook, all filtered through a specific discount rate and a tighter share count assumption that could subtly shift the per share picture.

Result: Fair Value of $23.87 (OVERVALUED)

However, that earnings path still faces pressure if price competition in Chinese express delivery remains intense or if heavy automation spending fails to deliver the expected cost savings.

Another View on Value

While the most popular narrative has ZTO Express (Cayman) slightly overvalued at $23.87 versus the $24.38 share price, the SWS DCF model points the other way, with an estimate of future cash flow value at $43.62. When two methods disagree this much, which one do you lean toward?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Frontline (FRO) is back in focus after reporting fourth quarter 2025 earnings that showed US$624.5 million in revenue and US$227.9 million in net income, along with ongoing fleet renewal and boardroom changes.

The earnings surprise and record dividend have arrived alongside powerful momentum, with a 35.25% 1 month share price return and an 84.40% year to date share price return feeding into a very large 5 year total shareholder return. Taken together, these factors suggest that sentiment has been strengthening rather than fading.

If Frontline’s recent move has you looking beyond tankers, this could be a good moment to check out 27 elite gold producer stocks as another way to uncover potential opportunities in commodity linked businesses.

With Frontline trading at US$37.95 against a US$32.00 analyst target but showing an intrinsic discount of around 24%, you have to ask yourself: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 18.6% Overvalued

Frontline’s most followed narrative pegs fair value at $32.00, which sits below the last close at $37.95 and frames the current valuation debate.

Recent research updates on Frontline highlight a mix of optimism on earnings power and some caution around how much of that is already reflected in the share price.

Want to see what underpins that fair value cut off point? The narrative leans on changing revenue expectations, higher profit margins, and a lower future earnings multiple. The mix is more subtle than it looks on the surface.

Based on this widely followed view, the fair value of $32.00 reflects updated assumptions on shrinking top line, wider margins, and a discounted future P/E, all run through a 8.15% discount rate. The result is a model that argues the recent share price strength has pushed Frontline above what those projections support today, even if the business continues to generate solid earnings.

Result: Fair Value of $32.00 (OVERVALUED)

However, the narrative can quickly look different if tanker oversupply returns or if tougher environmental rules raise costs faster than Frontline can adjust.

Another View: Cash Flows Point To Undervaluation

While the popular narrative flags Frontline as 18.6% overvalued at $37.95 versus a $32.00 fair value, our DCF model lands in a very different place. In that scenario, the shares trade about 24% below an estimated future cash flow value of $50.09. Which story do you think fits the business better?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Frontline for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

What Happened?

Shares of regional banking company SouthState (NYSE:SSB) fell 5.9% in the afternoon session after a broad sell-off in the financial sector was fueled by a hotter-than-expected inflation report and rising concerns over credit quality.

The latest Producer Price Index (PPI) data came in above expectations, reinforcing a narrative of sticky inflation and raising concerns that the Federal Reserve may have limited room for near-term easing. This news pressured the entire financial sector. The KBW Bank Index, a key benchmark for the banking industry, slumped as much as 6%, reflecting widespread investor anxiety. Compounding the issue were growing fears about credit woes, with one report noting that these concerns delivered a bruising selloff in shares of banks and asset managers.

The shares closed the day at $98.67, down 4.9% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy SouthState? Access our full analysis report here, it’s free.

What Is The Market Telling Us

SouthState’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 4 months ago when the stock dropped 5.8% on the news that disclosures from two lenders raised concerns about deteriorating loan quality across the industry. The drop was triggered by specific incidents that have spooked investors. Zions Bancorp announced a $50 million charge-off—a debt the bank doesn’t expect to collect—on a single loan. Separately, Western Alliance Bancorp revealed it was dealing with a borrower who had failed to provide proper collateral. These events are compounding existing anxieties about the regional banking sector, which is already under pressure from elevated interest rates and declining commercial real estate values. The news heightened investor concerns that more cracks could appear in borrowers’ creditworthiness, potentially leading to increased loan losses and reduced profitability for other banks in the sector.

SouthState is up 4.6% since the beginning of the year, and at $98.58 per share, it is trading close to its 52-week high of $107.82 from February 2026. Investors who bought $1,000 worth of SouthState’s shares 5 years ago would now be looking at an investment worth $1,214.

Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.

What Happened?

Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that inflation may be more entrenched than previously thought, potentially impacting future interest rate decisions. In response to the news, major market indices, including the S&P 500, Dow Jones, and Nasdaq, all traded sharply lower as investors reassessed the economic outlook.

The shares closed the day at $8.94, down 6.9% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Ocular Therapeutix? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Ocular Therapeutix’s shares are extremely volatile and have had 47 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

Ocular Therapeutix is down 25.2% since the beginning of the year, and at $8.84 per share, it is trading 45.1% below its 52-week high of $16.11 from December 2025. Investors who bought $1,000 worth of Ocular Therapeutix’s shares 5 years ago would now be looking at an investment worth $454.16.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas.